more RHETORIC ??? when is the chronic pain community going to see some POSITIVE ACTION ?

Chronic pain patients, overlooked in opioid crisis, getting new attention from top at FDA

https://amp.usatoday.com/amp/727015002

The Food and Drug Administration is working to address how the opioid epidemic response has affected chronic pain patients, who often can’t get relief.

Tough state laws on prescribing that took effect Sunday, Centers for Disease Control and Prevention (CDC) dosage guidelines and state and federal charges against doctors who prescribe opioids are an overreaction to addiction, according to several dozen people with unremitting pain who contacted USA TODAY. 

CDC researchers said in an article in April in the American Journal of Public Health that they overestimated the number of Americans who have died of prescription opioid overdoses. Because of inaccurate tracking methods, the CDC said it incorrectly counted many overdoses from illicitly manufactured synthetic opioids such as fentanyl as prescription drug deaths. 

The CDC had estimated 32,445 Americans died from overdoses involving prescription opioid pain medication in 2016. The CDC’s new estimate of fatal overdoses from prescription opioids is 17,087, or 53 percent of the original estimate.

Even though state laws say chronic pain patients who need medication will receive it, “that’s not what’s happening,” says Lauren Deluca of Worcester, Massachusetts, who founded the Chronic Illness Advocacy & Awareness Group last year after her own challenges getting the opioid painkillers she needed. 

The Food and Drug Administration (FDA) is trying to undo some of the damage through a host of actions that include a public meeting July 9 on chronic pain drug development and the challenges pain patients face in getting the treatment they need. 

Moriah White of Braxton County, West Virginia, calls herself an “opioid war casualty” and said she welcomes any help the government is willing to offer. She had to leave a job teaching special education because of the condition fibromyalgia, which makes her skin feel like “a sunburn scrubbed with a wire brush.”

Danny Elliott’s pain doctor was charged last week in a “takedown” in Florida and Georgia of 600 doctors accused of health care fraud and illegal opioid prescribing by Justice Department and Drug Enforcement Administration officials. The former pharmaceutical industry salesmen was electrocuted in1997, which left him with a traumatic brain injury that was so painful he contemplated suicide. He is trying to find a new doctor. His previous one was the first “who actually gave me some relief from my pain.”

DEA Miami Field Division Deputy Special Agent in Charge Jaime Camacho said last week that the agency is “committed to ending the opioid crisis that continues to plague Florida and endanger the welfare of our communities.”

Clinical psychologist Michael Schatman, editor in chief of the Journal of Pain Research, who describes himself as an “opioid moderatist,” said about 90 percent of people are better off without opioids.

But it’s the 10 percent who need them that are terribly harmed by policy and enforcement actions pushed by groups he said are “radically anti-opioids.” 

“For years, federal and state legislators did nothing, leaving it up to state medical boards and the regulatory agencies, which was the problem,” said Schatman, research director at Boston Pain Care, which has treated hundreds of patients without an overdose or suicide. “Now all of a sudden, state legislators are passing incredibly draconian laws that are and have the future potential to literally kill people.” 

He cited laws, such as one that took effect July 1 in states including Florida, that tighten regulation of doctors who prescribe opioids and other controlled substances. End-stage cancer patients and the elderly don’t have long enough to live to become addicted and  suffer needlessly because of the law, Schatman said.

Florida House Speaker Richard Corcoran, who attended the bill signing, defended the approach, according to the Orlando Sentinel.

“Is that an inconvenience? Yes,” said Corcoran. “Is an inconvenience worth saving 50,000 lives nationwide? Absolutely.”

That attitude has led some doctors whose patients have had no problems with opioid prescriptions to back away from prescribing them. Schatman said there’s a big difference between depending on opioids to survive and becoming addicted to them. 

Cathy Mitchell, a disabled registered nurse, suffers from a long list of injuries and diseases, including osteoarthritis, post-major lumbar surgery for ruptured discs, cervical scoliosis and bilateral carpal tunnel syndrome.

Disabled since 2013, she said only opioids provide the pain relief that allows her to “function daily.” 

She has to go to a pain clinic every 28 days and her primary care doctor every three months. After 10 years of being treated for  pain and anxiety “without causing any problems,” Mitchell can no longer be treated for both.

Making matters worse for what’s estimated to be millions of patients, the Centers for Medicare and Medicaid Services plans to drop coverage of opioid medications above a certain dosage starting next year. 

Elsewhere at the Department of Health and Human Services, the FDA’s plans include encouraging medical device development for pain and hosting a drug development meeting July 9 that focuses on how hard it is for patients with chronic pain to get treatment and what solutions exist. 

“The reality is that the opioid drugs work for certain patients, and there are certain situations where the opioids are the only drugs that work for those patients,” FDA Commissioner Scott Gottlieb said. 

The FDA’s success will be tested by the fact that physicians are largely policed by states and that even as opioid prescriptions go down, overdose deaths increase as many suffering from addiction have moved on to heroin, often in combination with other drugs. The FDA recommended that doctors reduce opioid prescriptions, but doctors and their medical societies remain opposed. 

State medical boards have been especially aggressive in some states going after the licenses of doctors for overprescribing opiate painkillers. 

Chronic pain patients across the country said that when physicians lose their license or stop treating pain patients, it can be difficult, if not impossible, to find a new doctor willing to take them on as a patient. 

In Virginia, then-Governor Terry McAuliffe boasted on a panel in October that the state led the nation in reductions in opioid prescribing, including a drop of a third in the prior six months. Doctors aren’t allowed to prescribe or refill a prescription for opioids for longer than 10 days without a written explanation. 

Two years ago, the state medical board suspended the license of Jenny Austin’s primary care doctor.

Austin, a former investment banker, had to take so much time off from work for crippling pain from migraines and a neurological disorder, she sought a higher dose of painkillers. She continued to see her Virginia doctor even after she moved to Louisiana, because she was “desperate to find a solution that would reduce my hospitalizations.”  

Instead, she’s out of work and bedridden much of the time. 

To help remedy this, the FDA is considering encouraging medical professional societies to develop evidence-based guidelines on appropriate prescribing and the possibility of incorporating new prescribing information on opioid painkiller labels. 

Schatman is skeptical the efforts will make much difference, in part because he said “there’s no empirical evidence that apps and other ‘medical devices’ can improve the quality of pain medicine in the United States.”

“The opioid pendulum has swung awry,” Schatman said. “This current climate of opiophobia is … leaving patients more dysfunctional, with diminished quality of lives, severe hopelessness and increasing suicidality in the chronic pain patient population.” 

 

As seen on the WEB !

Federal judge is taking testimonials from Pain patients he can order an injunction stopping the government from further restriction of opioids must have all comments by July 17th

Image may contain: text

What Every Patient Should Know About NarxCare

What Every Patient Should Know About NarxCare

www.painnewsnetwork.org/stories/2018/5/19/what-every-patient-should-know-about-narxcare

Walmart and Sam’s Club recently announced that by the end of August their pharmacists will start using NarxCare, a prescription tracking tool that analyzes real-time data about opioids and other controlled substances from Prescription Drug Monitoring Programs (PDMP’s).

Recent studies question the value of PDMP’s, but 49 states have implemented them so that physicians, pharmacists and insurers can see a patient’s medication history. Granted, there is a need for monitoring the select few who doctor shop and/or abuse their medications, albeit that number is only in the 2 percent range.

What is NarxCare? Appriss Health developed NarxCare as a “robust analytics tool” to help “care teams” (doctors, pharmacists, etc.) identify patients with substance use disorders. Each patient is evaluated and given a “risk score” based on their prescription drug history. According to Appriss, a patient is much more willing to discuss their substance abuse issues once they are red flagged as a possible abuser.

“NarxCare automatically analyzes PDMP data and a patient’s health history and provides patient risk scores and an interactive visualization of usage patterns to help identify potential risk factors,” the company says on its website.

“NarxCare aids care teams in clinical decision making, provides support to help prevent or manage substance use disorder, and empowers states with the comprehensive platform they need to take to the next step in the battle against prescription drug addiction.”

og_image.jpg

www.apprisshealth.com/solutions/narxcare/

Sounds great doesn’t it? Except prescription drugs are not the problem and never really have been. Illicit drug use has, is, and will continue to be the main cause of the addiction and overdose crisis. 

Even the name NarxCare has a negative connotation. “Narx” stands for narcotics. And in today’s environment, narcotics is a very negative word. NarxCare makes me feel like a narcotics police officer is just around the corner.

Each patient evaluated by NarxCare gets a “Narx Report” that includes their NarxScores, Overdose Risk Score, Rx Graph, PDMP Data and my favorite, the Red Flags. The scores are based on the past two years of a patient’s prescription history, as well as their medical claims, electronic health records and even their criminal history.

Ohio, Michigan, Indiana, Iowa, and several other states are using NarxCare to supplement their own PDMPs. And Walmart isn’t the only big retail company to adopt it. Kroger, Ralphs, Kmart, CVS, Rite Aid and Walgreens are already using NarxCare. There’s a good chance your prescriptions are already being tracked by NarxCare and you don’t even know it.

But NarxCare doesn’t just analyze opioid prescriptions. It also tracks other controlled substances, such as antidepressants, sedatives and stimulants. If a patient is on any combination of those drugs, their risk scores and their chances of being red flagged will be higher – even if they’ve been safely taking the medications for years.

There are several other ways a patient can be red flagged, such as having multiple doctors or pharmacies. But what if you moved and changed physicians? What if you had the same physician for many years and he/she retired or moved away? What if your pharmacy refused to fill your prescription and you had to go pharmacy hunting every month? What if you had dental surgery and your dentist placed you on a short-term pain medication?

Unfortunately, the NarxCare scores do not reflect any of that. How can raw data on prescription medications be an indicator of abuse? I believe there is some merit in tracking and weeding out the rare abuser, but NarxCare doesn’t factor in all the “what if’s” that can happen to law-abiding and responsible patients. 

As pain patients, we need to be acutely aware of the negative impact this analytics tool can have. Many of us have already been required to sign pain contracts, take drugs tests, and undergo pill counts. In 2019, Medicare will adopt policies making it even harder for patients to get high doses of opioid medication. Some insurers are already doing it. We’re already being policed enough as it is.

I intend to ask my physician, pharmacist and case manager if they utilize NarxCare. So should you. If they say yes, ask them why. Ask your doctor if they believe you are at risk for substance use disorder. Why is their judgement and treatment of you being second guessed by anyone?

This is the same company that sold a “bill of goods” to a number of states on using their database on the sale of Sudfed ( pseudoephedrine) used in making Meth.  The first time I used it … I said out loud … this is a stupid system… it won’t work… there is no validation of the driver’s license and once a person got a fake driver’s license past one pharmacist/tech… all you had to do was put in the driver’s license number and all the rest of the data lines auto filled .. and the Rx dept staff dropped into confirmation bias mode… and if the correct time had lapsed since the last purchase… it was approved to sell..  So the person with multiple fake driver’s license move on to the next pharmacy … gave them a different license and bought more… it took the state of Indiana several years for the legislature to figure this out and get out of the program and implement a new law.. that is slowing down the sale of Sudafed, but all along.  about 80% of meth was being imported from Mexico… so if nothing else it reduced the number of local meth labs.

I have heard all to often from pts about pharmacist being all about “the numbers” … this is just one more step for the corporate pharmacy chains to rescind the pharmacist’s professional discretion and dictate if this system shows certain data/parameters… the pharmacists is to refuse to fill.. won’t make any difference if the data is wrong or the artificial intelligence (AI) behind the determination is faulty…  all of these factors means “just say no”…..

Just imagine, all the sensational national news reports you have heard about these new self driving cars…  a few have crashed, one hit a pedestrian dressed in dark clothing walking across a unlighted multiple lane road at night…  How many cars crash in California.. how many make national news – all that is made by TELSA… that have semi-autonomous drive capability. At last count I think that the total TESLA fatal car crashes is 3 or4 and everyone made national news.

When this AI algorithm fails… it won’t make national news… because it will just be a denial of care… it will just be potentially throwing a pt into cold turkey withdrawal. The AI failures may never even be recognized because there will be no immediate/direct body count to make sensational national news ?

Since this appears to be a drive mostly by the chain pharmacies… this is just another good reason to move all your prescriptions to a independent pharmacy… where the pharmacist/owner may or may not be using it.. .but.. it will be his/her professional discretion as to believe what this AI program determines is red flags or not red flags and won’t have some corporate edict and threat of being fired if they don’t follow the corporate edict to the letter … no matter what their own professional opinion tells them is the right thing to do…

Here is a website to help anyone find a independent pharmacy by zip code https://ncpa.org/pharmacy-locator

We are going to start seeing falling numbers of opiate OD’s

Over the next year, we are going to see the number of opiate OD’s starting to slowly decline.. .and the bureaucrats are going to “shout from the rooftops” that Narcan has saved all of these lives and the forced reduction in legal opiate prescriptions was the other reason.

To a certain degree, that may be true for those addicts who got a hold of some mixture of illegal Fentanyl analog and Heroin and wasn’t aware of its potency and Narcan may have saved their ass and taught them a valuable lesson.. but.. did it solve their addiction problem and convinced them to get sober… maybe a few percent.

They are just going to find some other “safer” substance to abuse..  marijuana, alcohol, methamphetamine, cocaine, crack for starters and will probably be poly-substance abusers.  After all typically the current OD will have 4 to 7 substances show up in their toxicology..

I don’t see the bureaucrats understanding the real reason behind this drop in OD’s and will continue to push for less and less legal opiate prescribing for pain.. don’t want to go down that path again ?

What are they going to blame as the “gateway drug” for the substances that will end up being abused… alcohol is a legal product and Methamphetamine & Cocaine are legal prescription products… but.. little to none is prescribed to pts.

But if there is not a decrease – or only a slight decrease in OD’s – could be from the suicides of chronic pain pts who can’t stand their pain any longer and decide to put a final end to their pain.  But if they use their existing pain opiates … most likely their deaths will be labeled as a “opiate related death” if a opiate shows up in their toxicology.

Doing nothing more than providing more fodder for the bureaucrats to keep pressing for fewer and fewer opiate prescribed for pain management ?

Treatment for the opiate crisis – creating another crisis ? – who could have seen this coming ?

Kids’ Exposure to Buprenorphine Skyrockets

https://www.medscape.com/viewarticle/898671

The number of children aged 19 years and younger exposed to buprenorphine, an opiate widely prescribed to treat pain and opioid use disorder, has been rising since 2007, according to a study published online June 25 in Pediatrics.

Researchers led by Sara Post, MS, from the Center for Injury Research and Policy, The Research Institute, Nationwide Children’s Hospital, Columbus, Ohio, report that the overall exposure rate per million children increased by 215.6% during 2007 to 2010, going from 6.4 to 20.2. After dropping by 42.6% during 2010 to 2013 to 11.6 per million, it rose again by 8.6% to 12.6 per million in 2016.

Post’s group found that during 2007 to 2016, poison control centers in the National Poison Data System received reports of 11,275 children and adolescents with exposure to buprenorphine. Overall, 53.1% of exposures occurred in boys, and the mean age of affected children was a surprising 3.8 years.

Most of the exposures took place in residences, involved a single product, and occurred by ingestion. Overall, 21.2% of contacts with the drug had serious medical consequences such as respiratory depression, bradycardia, hypotension, and cyanosis, and 11 affected youngsters died.

Earlier this year, Medscape Medical News reported that pediatric opioid-related admission to intensive care units almost doubled during 2004 to 2015.

“Although buprenorphine is important for medication-assisted treatment of opioid use disorder, pediatric exposure to this medication can result in serious adverse outcomes,” according to senior author Gary A. Smith, MD, DrPH, from the Department of Pediatrics, College of Medicine, at The Ohio State University in Columbus.

The study looked at the age groups younger than 6 years, 6 to 12 years, and 13 to 19 years. Overall, 86.1% of contacts with the drug occurred in the youngest group, and 89.2% of contacts were reported as unintentional.

For single-substance exposures (97.3%), children younger than 6 years had greater odds of hospital admission and a serious medical outcome than adolescents aged 13 to 19 years. In those younger than 6 years, 48.1% of exposures led to hospital admission and 21.4% had a serious medical outcome, with seven deaths reported in this age group.

Adolescents aged 13 to 19 years made up 11.1% of exposures, and in this age category 77.1% of exposures were intentional, including 12.0% for suspected suicide attempts. More than a quarter of exposures (27.7%) involved the use of more than one substance. In this age group, 21.5% of exposures resulted in hospital admission and 22.0% in a serious medical outcome, including four deaths, all of which involved other substances such as alcohol or benzodiazepines.

But the exposure rate per million adolescents has declined: after increasing by 195.0% from 2.0 in 2007 to 5.9 in 2010, the rate dropped by 47.5% to 3.1 from 2010 to 2016, despite the widespread prescribing of this drug. As for the temporary overall drop in exposures during 2010 to 2013, the authors write, “One factor may be a shift in buprenorphine prescriptions to a population less likely to have young children in the home.”

According to the authors, prevention strategies are urgently needed and should be tailored to different stakeholders. Manufacturers, for instance, should use unit-dose packaging for buprenorphine products to reduce the chance of unintentional exposure. “Safe storage of all opioids, including buprenorphine, is crucial,” Smith said. “Parents and caregivers who use buprenorphine need to store it safely: up, away, and out of sight in a locked cabinet is best.”

In addition, healthcare providers need to warn childcare providers of the dangers of buprenorphine exposure and give instructions on safe storage and disposal. Adolescents should be informed of the risks of substance abuse and misuse. “Suspected suicide accounted for 12% of teen exposures, highlighting the need for access to mental health services for this age group,” Smith said.

One author was supported by a research stipend from the Center for Injury Research and Policy at Nationwide Children’s Hospital, funded by the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, and the Child Injury Prevention Alliance. One author has been retained to comment on a legal case involving buprenorphine. The other authors have disclosed no relevant financial relationships.

husband called Winn-Dixie corporate and they said the Pharmacist was just outright lying to you !

My husband was getting his medication at Winn-Dixie and had been getting it for several years and after 3 weeks of waiting the pharmacist told him he no longer fit the criteria and he asked what was that he said he didn’t know but corporate told them so my husband called corporate and they said he was just outright lying to you and then when he told us the pharmacies only get so much medication in the pharmacist is deciding who he wants to give it to and who he doesn’t want to give it to


In FL. you can only get 3 days worth up to 7 days if they had surgery. Primary Care Dr can’t write for any kind of narcotic. My husband was getting his medication at Walmart and the pharmacist contacted his doctor and wanted him to drop one pill every month until he was totally off of them. Well then what do you do? I don’t know if this is just in the State of Florida or in the whole country but each pharmacist carry their own license and it’s up to them if they want to fill your medication or not. My husband just got cut from 140 oxycodone 30 mg down to 112.


Walmart is no longer going to carry any type of narcotic. When he went to the doctor this past month they gave him a prescription for Narcan. They gave all of the patients a prescription


I was at a FL Board of Pharmacy (BOP) meeting in June 2015 and a chronic pain doc asked the board’s attorney if a pharmacist lying to a pt is against the pharmacy practice act (unprofessional conduct) and the attorney’s answer … paraphrase – there is nothing in the practice act that addresses that … apparently in FL the bar to be crossed – must be awful high – for the BOP to consider a pharmacist’s action guilty of unprofessional conduct ?

I have not read the FL Pharmacy practice act but most practice acts states that a pharmacy MUST STOCK MEDICATIONS that are commonly used in their market place… so any pharmacy stopping the stocking a  commonly used medication could be putting their pharmacy license at risk and/or getting fined.

Since the majority of legal opiates are prescribed/sold to those with some degree of chronic pain… could a store or chain that has decided to stop stocking opiates as a store/company policy be directly/indirectly  in violation of the Americans with Disability Act and Civil Rights Act and be guilty of a civil rights violation against a protect class of people/pts ? Something for a class action law firm and our court system to decide ?

 

The Myth of Morphine Equivalent Daily Dosage

The Myth of Morphine Equivalent Daily Dosage

https://www.medscape.com/viewarticle/863477

For far too many years, pain researchers and clinicians have relied on the concept of the morphine equivalent daily dosage (MEDD), or some variant of it, as a means of comparing the “relative corresponding quantity” of the numerous opioid molecules that are important tools in the treatment of chronic pain. This concept dates back to the mid-1980s, first appearing in the cancer pain treatment guidelines by Portenoy and colleagues,[1] and has subsequently been used empirically and clinically for a variety of purposes.

For example, researchers have relied on non-empirically derived “equivalent dosages” as a means to facilitate research in which opioid consumption serves as a dependent variable. Clinically, opioid “conversion” tables have been routinely used when switching a patient from one opioid to another. And, most unfortunately, opioid prescribing guideline committees have relied on this concept as a means of placing (usually arbitrary) limits on the levels of opioids that a physician or other clinician should be allowed to prescribe. Although these guidelines typically bill themselves as “voluntary,” their chilling effect on prescribers and adaptation into state laws[2] makes calling them “voluntary” disingenuous.

Although some scientists and clinicians have been questioning the conceptual validity of MEDD for several years, a recent study[3] has indicated that the concept is unequivocally flawed—thereby invalidating its use empirically and as a tool in prescribing guideline development. This analysis determined that a fundamental inadequacy of the MEDD concept is the lack of a universally accepted opioid-conversion method. The authors used survey data from pharmacists, physicians, nurse practitioners, and physician assistants to estimate daily morphine equivalents and found great inconsistency in their conversions of hydrocodone, fentanyl transdermal patches, methadone, oxycodone, and hydromorphone—illustrating the potential for dramatic underdosing or, in other cases, fatal overdosing.

Regarding the use of MEDD in research, our suspicion is that many pain investigators have known about the problems with this prodigiously flawed concept for many years. For example, in a 1991 Australian review of the polymorphic metabolism of opioids,[4] the authors concluded that “Pharmacogenetics may play an important role in explaining the wide variability of the clinical response to many opioid drugs.” Yet, a quarter of a century later, MEDD remains routinely used in pain research worldwide. Given that invalid dependent variables in research result in invalid findings, our hope is that investigators will begin to conduct studies comparing morphine with morphine, hydrocodone with hydrocodone, and so on—as opposed to relying on the standard (and far more convenient) approach of MEDD.

Implications in the Clinic

Clinically, prescribers need to use this information regarding the flawed MEDD concept to begin practicing dosage-switching and opioid rotation in a more thoughtful and scientific manner. Thus, even if the charts suggest that 1 mg of oxycodone is the “equivalent” of 1.5 mg of morphine, the practice of opioid rotation based on the concept of pharmacogentic homogeneity needs to be seriously reconsidered.

Furthermore, the evidence supporting pharmacogenomic differences among patients is mounting[5,6] and needs to be carefully weighed before labeling a patient who requires 30 mg of morphine rather than the prescriber’s “standard” of 10 mg in order to achieve adequate analgesia as an “addict.” Patients with chronic pain (particularly that of noncancer origin) who are reliant on opioid analgesia are already sufficiently stigmatized and marginalized[7] to allow this type of practice to continue to be the norm.

Although the use of MEDD in research and, to a greater extent, in practice, is probably due to unawareness of its inaccuracy, we posit that the use of MEDD by recent opioid guideline committees (eg, the Washington State Opioid Guideline Committee[8] and the Centers for Disease Control and Prevention Guideline Committee[9]) in the drafting of their guidelines is based more heavily on disregarding available evidence rather than ignorance. Furthermore, their misconduct in doing so has been more pernicious than the use of MEDD by researchers and individual clinicians, because these guidelines widely affect society as a whole as well as individual patients with persistent pain syndromes. We opine that these committees are strongly dominated by the antiopioid community, whose agenda is to essentially restrict opioid access—irrespective of the lack of data indicating that opioids cannot be a useful tool in the comprehensive treatment of carefully selected and closely monitored patients with chronic pain.

Although we emphatically agree that opioid analgesia should not be the first-line treatment for chronic noncancer pain, when other nonopioid treatments have either failed, are contraindicated medically or owing to behavioral and emotional factors, or are inaccessible because of the health insurance industry’s refusal to cover them (irrespective of their established evidence-bases), opioids should be considered. Guidelines that contain language suggesting that alternative treatments are regularly available when this is not the case are shortsighted and troubling.

Recently, we published an article in the Journal of Pain Research titled “The MEDD Myth: The Impact of Pseudoscience on Pain Research and Prescribing-Guideline Development,”[10] with Dr Jacqueline Pratt Cleary as our coauthor. This article goes into considerably more detail regarding the clinical and ethical imbroglio that we address in the current brief article, and as an open-access publication, the Journal of Pain Research encourages readers to access the full text at no cost here. We feel that the healthcare community must learn more about the need to work toward a paradigmatic revision in the consideration of opioids in research, clinical practice, and prescribing guideline development.

 

This individual committed suicide this morning because the pain was overwhelming

A twitter follower tweeted the following this morning at 4:27 AM: (Name and handle withheld)

Last tweet don’t bother responding I won’t be here. Or anywhere thanks for no one responding to my cry for help

This individual committed suicide this morning because the pain was overwhelming. HOW LONG ARE WE AS A SOCIETY GOING TO IGNORE CHRONIC PAIN SUFFERERS IN THIS BOGUS OPIOID HYSTERIA?
Don’t you understand that it only takes a split second to become a person with chronic pain? As citizens, we need to rise up against the war on pain.

TN: As of July 1, if you have a prescription for opioid drugs, you’ll see some changes when you go to the pharmacy

Here’s what new Tennessee opioid restrictions mean at your doctor’s office and pharmacy

https://www.knoxnews.com/story/news/health/2018/06/29/tennessee-opioid-prescription-law-pharmacy/746208002/

As of July 1, if you have a prescription for opioid drugs, you’ll see some changes when you go to the pharmacy.

That’s the date legislation related to Gov. Bill Haslam’s sweeping TN Together opioid reform takes effect.

Haslam budgeted more than $30 million in state and federal funds to attack the opioid epidemic through prevention, treatment and law enforcement.

More: Haslam signs TN Together, gives lifeline to state beset by opioid epidemic

Revolving door of despair: Drugs land more women behind bars

Election 2018: What do Tennessee candidates say about the opioid crisis?

Limits on supply, strength

The biggest change has to do with how much of a drug you can get and when.

Under the new law, pharmacists can only partially fill a prescription for no more than half of the number of days it’s written for.

And there are limits on prescriptions, too: General prescriptions are limited to a 10-day supply (and no more than 500 cumulative morphine milligram equivalents). Prescriptions after surgery are limited to a 20-day supply (maximum 850 cumulative MMEs). “Medical necessity” prescriptions are limited to a 30-day supply (maximum 1,200 cumulative MMEs). This law technically takes effect July 1, but it won’t be mandated until Jan. 1, 2019, to give pharmacies a chance to update their software.

Checking the database

When you bring an opioid prescription to be filled, the pharmacy is required by law check the Controlled Substance Monitoring Database, which logs each time you fill a prescription for a controlled substance. The database has to be checked when you first bring a prescription to a pharmacy, and then again at least once every six months as long as you’re getting refills.

The country is in the midst of an opioid epidemic. Did the FDA play a role in how we got here? Ayrika Whitney/USA TODAY NETWORK – Tennessee

Doctors’ documentation

When your doctor writes you a prescription for an opioid drug, the law now requires he or she document the specific reasons you’re getting the drug, as well as the fact that you’re getting it with informed consent — your prescriber has warned you it can be addictive.

Three-day supplies less restricted

However, doctors can write (and pharmacies can fill) opioid prescriptions for a three-day (or less) supply (maximum 180 MMEs) without these restrictions.

No ‘gag’ on pharmacists

Pharmacists no longer have any limits on discussing opioid-related issues with customers, including risks, effects and characteristics of the drugs; what to expect when you use it; the proper way to use it; and cost, with insurance or cash.

Some prescriptions exempt

Some prescriptions are exempt from the requirements and limits, though doctors must still write a diagnosis code and “exempt” on them: Prescriptions for people who are getting palliative cancer treatment or hospice care; who have sickle cell disease; who are inpatients at licensed facilities; who are seen by doctors who meet the state requirements to be “pain management specialists”; who were treated with opioids for 90 days or more; who have severe burns or “major physical trauma”; and who are on methadone, buprenorphine or naltrexone, which are drugs used to assist recovery from addiction.

Initially, the legislation was more restrictive — prompting concern from pharmacists that it would prevent “legitimate patients” from being able to get needed prescriptions and put a burden on pharmacists, said the Tennessee Pharmacists Association, which lobbied legislators for some changes.

But the organization said in a statement that decreasing the prescription drug supply must be combined with access to treatment and recovery services, or it may increase both the number of people using illicit street drugs and the number of pharmacy burglaries/robberies.

“While this legislation is well-intended, TPA remains concerned about the unintended consequences of the legislation on patients and the pharmacy profession,” the Tennessee Pharmacists Association said. “Decreasing the overall epidemic of prescription drug abuse and reducing patients’ risk of dependence are commonly shared goals of all pharmacy professionals and Tennesseans. However, the need for patient access to treatment and recovery services has never been greater, and our state must continue to seek solutions which help our patients struggling with dependence and addiction to get the help they desperately need.”

This is the first time that I have heard about this… but.. then again.. I don’t live in TN. I think that I need to place the state of TN and all the bureaucrats that are in charge of protecting the citizens of TN. at the TOP OF MY MORON LIST !  I just hope that other states don’t take TN’s policies as a guideline for other states to follow.

It sure sounds like the state of TN is only interested in addiction… those who have chronic pain issues .. they are left to deal on their own… if the numbers are correct…  it appears that chronic pain pts will be limited to 40 MME/day…  that is 4 Vicodin 10/day… I don’t think that would allow a Fentanyl patch 12 mcg nor would it allow the smallest Morphine SR 15 q 8 hrs.  This is LESS THAN HALF OF WHAT THE CDC GUIDELINES STATED FOR ACUTE PAIN..

USA TODAY reporter “wants your denial of pain management story “

If you suffer from chronic pain, I’d like to know how the state and federal government response to the opioid epidemic has affected you. DM me or email jodonnell@usatoday.com

 

 

article now published

https://amp.usatoday.com/amp/727015002